Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Interest & Investment Income (2021 - 2025)

SAB Biotherapeutics' Interest & Investment Income history spans 5 years, with the latest figure at $700739.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 413.84% year-over-year to $700739.0; the TTM value through Dec 2025 reached $1.4 million, up 11.36%, while the annual FY2025 figure was $1.4 million, 11.36% up from the prior year.
  • Interest & Investment Income reached $700739.0 in Q4 2025 per SABSW's latest filing, up from $655233.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $700739.0 in Q4 2025 to a low of $3769.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $169859.1, with a median of $29248.5 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 1829.64% in 2024, then plummeted 96.38% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $8544.0 in 2021, then skyrocketed by 250.29% to $29929.0 in 2022, then skyrocketed by 1517.31% to $484046.0 in 2023, then tumbled by 71.83% to $136374.0 in 2024, then surged by 413.84% to $700739.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Interest & Investment Income are $700739.0 (Q4 2025), $655233.0 (Q3 2025), and $13562.0 (Q2 2025).